
Research in AI for Protein Design @Harvard | Prev. CS PhD @UniofOxford, Maths & Physics @Polytechnique
Boston
Joined September 2020
- Tweets450
- Following407
- Followers1.4K
- Likes1.9K
Pascal Notin retweeted
Binder design is nice and all, but here we have three agents sharing data and autonomously controlling a lab to design enzymes with shifted substrate scopes and high activity!
@cobanbrooks @NotinPascal @romerolab1
Pascal Notin retweeted
I’m really excited to share our new preprint, out today, where we built a fully autonomous system for enzyme engineering — integrating a self-driving lab with a generative protein language model that worked together over a month to engineer substrate specificity in glycoside hydrolase (GH1) enzymes.
biorxiv.org/content/10.64898…
[1/n]
Pascal Notin retweeted
Now available as its peer-reviewed version in Nature:
nature.com/articles/s41586-0…
Thrilled to share our new paper where we introduce a multiplexed hydrogen–deuterium exchange MS (mHDX‑MS) method that can measure hundreds of protein domains’ conformational energy landscapes—all in a single experiment!
biorxiv.org/content/10.1101/…
Pascal Notin retweeted
Quite pleased to hear that one of my submitted proteins placed #5 out of 1200 that were tested in this lovely competition. The approach: pure rational design. Nice to see that human + Microsoft Word is still competitive with state-of-the-art AI methods 🙂
The results of the Nipah Protein Design Competition are out!
🧬 1200 proteins experimentally validated (3x more than last year)
📈 99 novel binders against the target protein (a challenging tetramer with little prior work)
💪 26 single digit nM or better binders, with the best ones at single-digit picomolar affinity!
All data now available open-source on Proteinbase!
Let's take a look at the results ⬇️
Pascal Notin retweeted
Super excited to share that I will join @Princeton @omenndarlingbio this Fall as an assistant professor. We combine syn bio and AI to program macromolecules and cells for therapeutics engineering and drug target discovery. jianglab.bioengineering.prin…
Pascal Notin retweeted
New paper “Proteome-wide model for human disease genetics” is now live at Nature Genetics: rdcu.be/eRu7K
popEVE (pop.evemodel.org) finds the needles in the haystacks of human genetic variation:
Pascal Notin retweeted
Reminder - PhD applications for OATML are now open
The first funding deadline is December 2 - candidates interested in developing Bayesian deep learning methodology, applications of ML, AI security, and understanding ML methodology are encouraged to apply
More info: oatml.cs.ox.ac.uk/apply.html
Pascal Notin retweeted
Thrilled to announce I'm starting as a Principal Investigator at #Aithyra in Vienna! We'll be developing generative models to understand cell biology and design proteins.
I'm hiring PhDs, Postdocs, & Visiting Researchers! PhD applications by Sept 10: apply.cemm.at
Pascal Notin retweeted
Our paper on generalizable antibody-antigen binding affinity prediction has been featured on the cover of the August Issue of @NatComputSci! 📔🎉
🚨Our August issue is now live and includes research on antibody-antigen binding, molecular screening for zeolite synthesis, psychological experiments with LLMs, and much more!
nature.com/natcomputsci/volu…
Pascal Notin retweeted
I’ve thoroughly enjoyed reading two (VERY!) recent papers that model protein sequences by retrieving evolutionary information (dynamically) at inference time, and there's a lot to unpack!
[1] arxiv.org/abs/2506.08954
[2] biorxiv.org/content/10.1101/…
(1/n)
Pascal Notin retweeted
A generative artificial-intelligence tool has designed a synthetic CRISPR system that successfully edits human DNA
go.nature.com/3JadkRy
Pascal Notin retweeted
1/5 Biological data is noisy, redundant, and ever-growing. 🗣️
In our new paper (first paper of my post doc!! ⚡️), we track model performance across 14 years of UniRef100 snapshots to ask: how does pLM performance scale with training data?
Pascal Notin retweeted
AI expands the repertoire of CRISPR-associated proteins for genome editing
@NatureNV preview by @NotinPascal
nature.com/articles/d41586-0…
@thisismadani profluent.bio/ @jeffruffolo @AadyotB et al
nature.com/articles/s41586-0…
Pascal Notin retweeted
1/4
🚀 Announcing the 2025 Protein Engineering Tournament. This year’s challenge: design PETase enzymes, which degrade the type of plastic in bottles. Can AI-guided protein design help solve the climate crisis? Let’s find out! ⬇️
#AIforBiology #ClimateTech #ProteinEngineering #OpenScience
Pascal Notin retweeted
Save the date! Machine Learning for Drug Discovery (MLDD) is happening soon on Monday 30 June, 2025.
MLDD aims to bring together ML for drug discovery experts, innovators, and enthusiasts from the machine learning, biotechnology and drug discovery domains in London, UK to converge, exchange ideas, and forge new paths in revolutionizing therapeutic development.
This year, we are very fortunate to feature keynotes by:
- Charlotte Brunne (EPFL)
- John Chodera (Achira / MSKCC)
- Kexin Huang (Stanford University)
- Jacob Kimmel (NewLimit)
- Marinka Zitnik (Harvard University)
To accommodate the worldwide community, the event will be held fully remotely this year - a link to join and further information are provided at the MLDD website (link in thread below!)
Looking forward to seeing you there!
Pascal Notin retweeted
What would our data landscapes look like if we could biochemically characterize 100s, 1000s, 10^n evolutionary sequences?
Papers like this make strides towards that moonshot dream!! Such neat work from @MargauxPinney lab!
science.org/doi/10.1126/scie…
Pascal Notin retweeted
As sequence databases get bigger and more diverse, retrieval-based methods provide an interesting alternative to scaling successively bigger protein language models. (1/5)
Pascal Notin retweeted
End-to-end differentiable homology search for protein fitness prediction.
@ruben_weitzman @lood_ml @yaringal @deboramarks @NotinPascal
Pascal Notin retweeted
🚨 New in @ImmunityCP !
EVE-Vax, an AI model that anticipates future viral evolution and designs antigens to proactively test vaccines + therapeutics—before variants even emerge.
We envision this work will help make future-proofed vaccines and therapeutics.
👇 (1/7)





































